glp-1 summit Home Full Event Guide - 3rd

doi:10.1152/ajpcell.00296.2010 76

The Ozempic vision loss lawsuit involves claims that semaglutide medications, including Ozempic, Wegovy, and Rybelsus, may be associated with non-arteritic anterior ischemic optic neuropathy (NAION), a rare optic nerve condition that can cause sudden, permanent vision loss

The current UK regulatory position maintains that: GLP-1 receptor agonists remain authorised for their approved indications (type 2 diabetes management for all agents

[55] Joseph A

New insights into the anti-diabetic actions of metformin: from the liver to the gut

Identifying genetic predispositions to gastric sensitivity helps your provider anticipate heartburn risk and adjust your starting dose accordingly, reducing side effect severity before it starts